Cancer cells can use this pathway as an additional or alternate mitogenic pathway to signaling via the type-1 IGF receptor (IGF-1R), and can provide a mechanism by which cancer cells can become resistant to treatments targeting the IGF-1R (4, 12). The gene discussed is IGF1R; the disease is cancer.